NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin
Estimated value
—
Awarded value
—
Suppliers
9
Lots
1
Published
30 Jan 2026
Description
Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026 Offer reference number: CM/TNS/25/5735 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin Lot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months) Lot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months) Lot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Scope
- Reference
- C386886
- Commercial tool
- Standalone contract
- Contract dates
- 01 Feb 2026 to 30 Sept 2027Possible extension to 30 Sept 2029
Option or options to extend (at the discretion of the Authority) up to a maximum of 24 months
- CPV classifications
- 33600000
- Contract locations
- North East England, United KingdomNorth West England, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomEast of England, United KingdomSouth East England, United KingdomSouth West England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion | price | 100.00% |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded suppliers· 9 suppliers
Awarded —
Other contracts from NHS England
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to ZENTIVA PHARMA UK LIMITED· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 09 Jun 2026 |
| NHS National Generics Pharmaceuticals - Supply Chain Resilience | contract | — | 01 May 2026 |
| NHS National Branded Interim - 1 June 2026 | contract | — | 16 Apr 2026 |
| NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide | contract | — | 26 Mar 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | contract | — | 26 Feb 2026 |
| NHS National Framework for Transition Products (Nintedanib and Dalbavancin) | contract | — | 25 Feb 2026 |
| Transitional Drugs 6 | contract | — | 04 Feb 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | contract | — | 14 Jan 2026 |
| Generic, Branded Generic & Proprietary Medicinal Products - Group 17 | contract | — | 12 Jan 2026 |
| NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin | contract | — | 26 Nov 2025 |